Posted by Michael Wonder on 16 Jan 2024
NRx Pharmaceuticals announces FDA qualified infectious disease product and fast track designation of NRX-101 in complicated urinary tract infection and pyelonephritis
16 January 2024 - QIDP designation grants priority review and an additional 5 years of additional product exclusivity.
NRx Pharmaceuticals today announced that it has received qualified infectious disease product and fast track designation from the US FDA for NRX-101 in the treatment of complicated urinary tract infections and pyelonephritis.
